About
Cecilia Jones joined Agios as chief financial officer in September 2022. She has more than 20 years of financial experience within the biopharmaceutical industry, including several companies focused on rare diseases.
Before joining Agios, she served as chief financial officer at LogicBio, where she was responsible for the company's financial strategy, including evaluation of financing alternatives and analysis of business development opportunities, as well as corporate financial planning, accounting, corporate communications and investor relations. Prior to that, she spent more than 10 years at Biogen in roles of increasing responsibility within the finance organization, most recently as vice president of R&D, worldwide medical and business development finance.
Roles
Agios Pharmaceuticals, Inc.
Chief Financial Officer · Current role
Sep 2022–present
LogicBio Therapeutics
Chief Financial Officer · Gene therapy company.
Jan 2021 – Sep 2022
Biogen
Vice President, Finance · Joined Biogen in November 2010 in a variety of finance roles.
Jun 2019 – Jan 2021
Biogen
Senior Director, Corporate Finance
Jul 2015 – Jun 2019
Interactive Data Corporation / Genzyme
Financial planning and analysis roles
—
LogicBio
Chief Financial Officer · Led the company's financial strategy, financing evaluation, business development analysis, financial planning, accounting, corporate communications and investor relations.
—
Biogen
Vice President, R&D, Worldwide Medical and Business Development Finance · Spent more than 10 years in roles of increasing responsibility within the finance organization, advising senior management on investment prioritization.
—
Fixed Compensation
FY 2025
All other compensation
$15,961
Performance Compensation
Data from FY 2025
Cash incentive
Non-equity incentive plan compensation
$240,789
Stock awards
Also at Agios Pharmaceuticals, Inc.